References
- McCann UD, Ricaurte GA. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosc Biobehav Rev 2004;27:821–826
- Mack AH, Frances RJ, Miller SI. Clinical textbook of addictive disorders. 3rd ed. New York: The Guilford Press; 2005. p. 207. ISBN 1-59385-174
- Logan BK. Methamphetamine – effects on human performance and behavior. Forensic Sci Rev 2002;14:134--151
- Brecht ML, O’Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav 2004;29:89–106
- Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat 2003;24:267–277
- Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009;104:1085–1099
- McCann UD, Ricature GA. Amphetamine (or Amphetamine-like)-related disorders. In: Sadock BJ, Sadock VA, Ruiz P. eds. Kaplan and Sadock’s comprehensive textbook of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009:1288–1296
- Leamon MH, Gibson DR, Canning RD, Benjamin L. Hospitalization of patients with cocaine and amphetamine use disorders from a psychiatric emergency service. Psychiatric Services 2002;53:1461–1466
- Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev 2010;29:12–20
- McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101:1473–1478
- Sommers I, Baskin D, Baskin-Sommers A. Methamphetamine use among young adults: health and social consequences. Addict Behav 2006;31:1469–1476
- Leamon MH, Flower K, Salo RE, Nordahl TE, Kranzler HR, Galloway GP. Methamphetamine and paranoia: the methamphetamine experience questionnaire. Am J Addictions 2010;19:155–168
- Caton CLM, Hasin DS, Shrout PE, Drake RE, Dominguez B, First MB, Samet S, Schanzer B. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiat 2007;190:105–111
- Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg E-M, Medhus S, et al. Amphetamine-induced psychosis – a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiat 2012;12:221
- Zarghami M. Methamphetamine has changed the profile of patients utilizing psychiatric, emergency services in Iran. Iran J Psychiat Behav Sci 2011;5:1--5
- McKetin R, McLaren J, Lubman DI, Hides L. Hostility among methamphetamine users experience psychotic symptoms. Am J Addict 2008;17:235–240
- Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai 2005;88:S43–S52
- Marder SR, Hurford IM, Van Kammen DP. Second generation antipsychotics. In: Sadock BJ, Sadock VA, Ruiz P. eds. Kaplan and Sadock’s comprehensive textbook of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009:3214–3218
- First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR Axis I disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002
- Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiat 1982;39:784–788
- Andreasen N. Scale for the assessment of positive symptoms. Iowa City, IA: University of Iowa; 1984